G1 Therapeutics

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 1, 2023
Survival, Patient, Research, SCLC, Patent, Event, Food, PIN, Pivotal, Thrombocytopenia, Public expenditure, SG, RESEARCH, Telephone, Organization, GAAP, Wind, Total revenue, Acquisition, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, R, TNBC, Update, Clinical trial, Security, Webcast, Interim, Avelumab, Guideline, Anemia, G1 Therapeutics, Net, Therapy, Hospital, PARK, OS, Regenerative Medicine Advanced Therapy, Neutropenia, ASCO, Acceleration, Shanda, Pharmaceutical industry, Video game, Fine chemical, Cryptocurrency, Simcere Pharmaceutical, G1

Recognized $10.8 Million in Net COSELA Revenue: G1 recognized total revenues of $12.3 million for the third quarter of 2023.

Key Points: 
  • Recognized $10.8 Million in Net COSELA Revenue: G1 recognized total revenues of $12.3 million for the third quarter of 2023.
  • Vial volume grew 3% over the second quarter of 2023 despite the impact of an ongoing platinum-based chemotherapy shortage.
  • Ended the Third Quarter of 2023 with Cash, Cash Equivalents, and Marketable Securities of $94.4 Million.
  • Operating expenses for the third quarter of 2023 were $28.7 million, compared to $45.1 million for the third quarter of 2022.

Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Retrieved on: 
Friday, October 27, 2023
Survival, Inovalon, Patient, G1 Therapeutics, American Society of Clinical Oncology, Medicare, Thrombocytopenia, EMOL, RESEARCH, Observational study, HRU, PPPM, Aplastic anemia, ESA, Cytopenia, Society, King Fahad Specialist Hospital Dammam, RBC, Risk, G-CSF, Anemia, Therapy, Hospital, PARK, Neutropenia, ASCO, Pharmaceutical industry, Medical imaging, Health insurance, Trilaciclib

1.2% of trilaciclib-treated patients had grade ≥3 HAEs in ≥2 lineages compared to 13.5% of patients in the comparison cohort.

Key Points: 
  • 1.2% of trilaciclib-treated patients had grade ≥3 HAEs in ≥2 lineages compared to 13.5% of patients in the comparison cohort.
  • Assessment of Hospitalizations and Cytopenia Events Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Chemotherapy with Trilaciclib (Huang, H. et al.)
  • Burden of Myelosuppression in Extensive-Stage Small-Cell Lung Cancer Patients Receiving Chemotherapy: Retrospective Analysis of Real-World Data from Tennessee Oncology (Blakely, L.J.
  • These findings suggest that how patients present in their initial visits are not necessarily predictive of myelosuppressive events.

G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)

Retrieved on: 
Wednesday, October 18, 2023
G1 Therapeutics, SCLC, ASCO, Incidence, American Society of Clinical Oncology, Physician, RESEARCH, Bone marrow, Cancer Care Ontario, Carcinoma, Society, Trilaciclib, Khorshid, Therapy, PARK, Patient, Medical imaging

RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that COSELA® (trilaciclib) has been recommended as a myeloid supportive agent in the updated American Society of Clinical Oncology (ASCO) small cell lung cancer (SCLC) guidelines for patients with untreated or previously treated extensive-stage small cell lung cancer (ES-SCLC) who are undergoing treatment with chemotherapy or chemoimmunotherapy.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that COSELA® (trilaciclib) has been recommended as a myeloid supportive agent in the updated American Society of Clinical Oncology (ASCO) small cell lung cancer (SCLC) guidelines for patients with untreated or previously treated extensive-stage small cell lung cancer (ES-SCLC) who are undergoing treatment with chemotherapy or chemoimmunotherapy.
  • COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for ES-SCLC.
  • “The inclusion of COSELA in these new ASCO SCLC guidelines is essential, as they inform treatment decisions by U.S. physicians caring for people living with small cell lung cancer,” said Raj Malik, M.D., Chief Medical Officer of G1 Therapeutics.
  • For more information on ASCO’s guidelines in thoracic cancer, including the SCLC guidelines, please follow this link .

G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023

Retrieved on: 
Wednesday, October 18, 2023
RESEARCH, Telephone, G1 Therapeutics, Therapy, PARK, Event, Webcast, PIN, Clothing, Online shopping, Interior design

RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the third quarter 2023 on Wednesday November 1, 2023, at 8:30 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the third quarter 2023 on Wednesday November 1, 2023, at 8:30 a.m.
  • Please note that there is a new process to access the call via telephone.
  • While not required, it is recommended that you join 10 minutes prior to the start of the event.
  • A live and archived webcast will be available on the Events & Presentations page of the company’s website: www.g1therapeutics.com .

G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium

Retrieved on: 
Monday, October 16, 2023
King Fahad Specialist Hospital Dammam, Abstract, Research, Society, American Society of Clinical Oncology, RESEARCH, AM, Cytopenia, Therapy, G1 Therapeutics, Patient, PARK, ASCO, Pharmaceutical industry, Medical imaging, Flour, Bone marrow suppression

RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that multiple abstracts have been accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, held October 27th and 28th in Boston, MA.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that multiple abstracts have been accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, held October 27th and 28th in Boston, MA.
  • A copy of the posters will be made available on the G1 Therapeutics website following the presentations here .
  • “The important research being presented at this year’s ASCO Quality Care Symposium highlights the significant burden of chemotherapy-induced myelosuppression and the real-world clinical impact of treatment with trilaciclib in patients with extensive-stage small cell lung cancer," said Raj Malik, M.D., Chief Medical Officer of G1 Therapeutics.
  • Burden of Myelosuppression in Extensive-Stage Small-Cell Lung Cancer Patients Receiving Chemotherapy: Retrospective Analysis of Real-World Data from Tennessee Oncology.

Black Diamond Therapeutics Announces CEO Transition

Retrieved on: 
Monday, September 18, 2023
Diamond, Yale New Haven Hospital, Gilead Sciences, Yale University, Executive, Senior, G1 Therapeutics, ARCH Venture Partners, Senior advisor, Food and Drug Administration, Cancer, Black Diamond, Washington University in St. Louis, Gilead, Patient, Chairperson, Drug discovery, Faculty, Growth, CGI, FDA, Leukemia, IND, Food, Corporate development, Pharmaceutical industry, Nursing, G1

CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer (CEO) effective immediately. Dr. Velleca succeeds Company CEO and co-founder, David M. Epstein, Ph.D., who has stepped down and will continue to serve on the Board of Directors of the Company.

Key Points: 
  • and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology company developing therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that current Chairman of the Board, Mark Velleca, M.D., Ph.D., has been appointed as Chief Executive Officer (CEO) effective immediately.
  • Dr. Velleca succeeds Company CEO and co-founder, David M. Epstein, Ph.D., who has stepped down and will continue to serve on the Board of Directors of the Company.
  • Prior to joining the Black Diamond Board, Dr. Velleca served as CEO of G1 Therapeutics, Inc. (Nasdaq: GTHX).
  • Most recently, Dr. Velleca was CEO of StrideBio, a gene therapy company, and a Venture Partner at Hatteras Venture Partners.

G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 5, 2023
RESEARCH, Therapy, G1 Therapeutics, Conference, PARK, Rare-earth element, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Communications Officer Will Roberts will provide a corporate presentation on September 12, 2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global Investment Conference.

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, September 1, 2023
RESEARCH, Employment, Therapy, RSU, G1 Therapeutics, PARK, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,800 shares of G1’s common stock and 3,300 restricted stock units (RSUs) to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,800 shares of G1’s common stock and 3,300 restricted stock units (RSUs) to two hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”).
  • These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).
  • The Amended and Restated 2021 Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of G1 (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with G1, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The stock options and RSUs are subject to the terms and conditions of the Amended and Restated 2021 Plan.

G1 Therapeutics to Participate in Two August Investor Conferences

Retrieved on: 
Monday, July 31, 2023
RESEARCH, G1, Therapy, G1 Therapeutics, Conference, PARK

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August investor conferences.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that it will participate in two August investor conferences.
  • On Monday August 7, 2023, G1’s Chief Executive Officer Jack Bailey and other members of G1’s Executive Team will participate in the 2023 BTIG Virtual Biotechnology Conference.
  • BTIG-hosted events are intended for prospective and existing BTIG clients only.
  • On Wednesday August 9, 2023, the G1 team will also participate in one-on-one meetings with institutional investors during the 2023 Wedbush PacGrow Healthcare Conference in New York City.

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Retrieved on: 
Monday, July 31, 2023
Regenerative Medicine Advanced Therapy, Prevalence, G1 Therapeutics, RESEARCH, Neutropenia, Patient, Quality of life, Therapy, PARK, Blue, Pharmaceutical industry, Trilaciclib, Thrombocytopenia, Anemia

RESEARCH TRIANGLE PARK, N.C., July 31, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the publication of real world outcomes data from published and new unpublished studies showing the potential of trilaciclib to reduce single and multilineage myelosuppressive events associated with chemotherapy, cytopenia-related healthcare utilization, and hospitalizations in adults being treated for extensive stage small cell lung cancer (ES-SCLC). This review of real-world experience with trilaciclib was published in Advanced Therapy.

Key Points: 
  • “The findings add to the growing body of evidence supporting the benefits of trilaciclib that were demonstrated in the clinical trials that led to its approval.
  • Outcomes were compared qualitatively between the trilaciclib and historical non-trilaciclib reference groups, and between first line trilaciclib initiators and the overall trilaciclib population.
  • Trilaciclib patients also had numerically fewer all-cause hospitalizations and shorter length of stay in reference to the historical non-trilaciclib patients.
  • Lower average rates of dose reduction and treatment delays were observed among patients receiving trilaciclib in reference to the historical non-trilaciclib cohorts.